Hospira is voluntarily recalling two lots of naloxone hydrochloride injection, used to treat opioid overdoses, because they may contain particulate matter on the syringe plunger, the Food and Drug Administration announced yesterday. The lots were distributed to hospitals, wholesalers and others in the United States, Puerto Rico and Guam. The company has notified hospitals and others to arrange for return of the recalled product, which should not be used or distributed. Adverse reactions or quality problems associated with the products may be reported to the FDA's MedWatch program. No adverse events have been reported to date.

Related News Articles

Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe…
Headline
The Food and Drug Administration yesterday warned the health care community about complications that arise when pairing pain medications with intrathecal…
Headline
Oct. 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The Food and Drug Administration yesterday released a series of guidance documents intended to help manufacturers develop generic transdermal and topical…